Condition: Heart Failure · Chronic Kidney Diseases · Sponsor: Fundación para la Investigación del Hospital Clínico de Valencia
Heart failure (HF) and Chronic Kidney Disease (CKD) patients are frequently not administered renin-angiotensin aldosterone system inhibitor (RAASi) therapies at recommended doses due to hyperkalaemia, despite proven mortality and morbidity benefits. Sodium zirconium cyclosilicate (SZC) is a nonabsorbed potassium binder proven to lower serum potassium (S-K) and maintain normokalaemia. The purpose is to assess if a treatment regimen containing SZC will allow RAASi therapies to be optimized to target doses in patients with heart failure, chronic kidney disease and elevated serum potassium or at risk of developing elevated serum potassium.
This description comes directly from the study's public registry record.
Clara Bonanad Lozano · +34 963156181 · clarabonanad@gmail.com
Always discuss trial participation with your own doctor first.
| Hospital Universitario Fundación Alcorcón | Alcorcón, Madrid, Spain | Not Yet Recruiting |
| Hospital Universitario Severo Ochoa | Leganés, Madrid, Spain | Not Yet Recruiting |
| Hospital Universitario Nuestra Señora del Perpétuo Socorro | Albacete, Spain | Recruiting |
| Hospital Universitario de Burgos | Burgos, Spain | Recruiting |
| Hospital Universitario Reina Sofía | Córdoba, Spain | Not Yet Recruiting |
| Hospital Clínico Universitario de Valencia | Valencia, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06578078